Sanofi Pasteur
 |
|
| Public | |
| Founded | August 2004 by merger |
| Headquarters | Lyon, France |
|
Key people
|
David Loew Executive Vice President, Vaccines |
| Revenue | €4.74 billion (2015) |
|
Number of employees
|
15,000 |
| Parent | Sanofi |
| Website | sanofipasteur.com |
Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.
Sanofi Pasteur is one of four global producers of the yellow fever vaccine.
In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group, changed its name to Sanofi Pasteur. In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable.Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks will run out in June 2016.
Sanofi Pasteur
In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. The Toronto Sanofi plant On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.
...
Wikipedia